To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.
The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).
InformationThe information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.
A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin
A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme
A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
A Biomarker-Driven Master Protocol for Previously Treatment Squamous Cell Lung Cancer (Lung-Map)
Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
Radiotherapy with Temozolomide versus Radiotherapy with PCV Chemotherapy for 1p/19q Co-deleted Anaplastic or Low Grade Glioma
POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib, Savolitinib, and Sunitinib in Metastatic Papillary Renal Carcinoma (PAPMET)
TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2 negative early breast cancer